Zhongzhi Pharmaceutical (HKG:3737) said its net profit is expected to fall by more than 70% in 2025 from a year earlier, according to a Jan. 23 Hong Kong bourse filing.
Shares of the firm were down over 5% in Monday morning trade.
The company said the decline was mainly driven by short-term revenue pressure following adjustments in industry policies, which weighed on sales and profitability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.